A Case-control Study On The Efficacy And Economic Evaluation Of Glimepiride Or Glibenclamide Combined With Metformin,Sagelettingin The Treatment Of Type 2 Diabetes Mellitus

Objection:Systematic evaluation of the efficacy,safety and economic cost of Glibenclamide combined with Sageletting and metformin in the treatment of type 2 diabetes mellitus compared with glimepiride combined with Sageletting and metformin,to provide based evidence for clinical reference.Method:120 patients with type 2 diabetes mellitus were randomly divided into two groups.A group:Glibenclamide combined with Sageletting and metformin;B group:Glimepiride combined with Sageletting and metformin.The course of treat-ment is 12 weeks.The changes and adverse reactions of fasting blood glucose,post-meaL bLood glucose,glycosylated hemoglobin,fasting C-peptide,postmeal 2-hour C-peptide,fasting proinsulin,postmeal 2-hour proinsulin,postmeal 2-hour insulin,body weight,insulin resistance index and so on were observed.Result:Both 2 groups had good effects on reducing abdominal blood glucose,2 h postmeal blood glucose and glycosylated hemoglobin,fasting insulin and C peptide water increased significantly in both groups,while fasting proinsulin and proinsulin after meal 2 hours both decreased.There was no significant difference in the incidence of hypoglycemia between the two groups,and there was no significant increase in body weight after 12weeks treatment in both two groups.The economic cost of group A was significantly lower than that of group B.Conclusion:Glimepiride and glibenclamide separately combined with Sageletting and metformin are effective in the treatment of type 2 diabetes mellitus.Hypoglycemia response is low.The economic cost of glibenclamide group was significantly lower than that of glimepiride group.